Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT Combined With Anlotinib for Brain Metastases From NSCLC
NCT06476093Recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by First People's Hospital of Lianyungang City. Primary endpoints: intracerebral Progression-Free Survival at 20 months and intracerebral Objective Response Rate at 20 months. Started Jul 2024; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06476093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06476093.